YD Bio Limited
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Revenue | $596.8K | $510.4K | $350.1K |
| Cost of Revenue | $429.4K | $355.0K | $196.7K |
| Gross Profit | $167.4K | $155.4K | $153.4K |
| Gross Margin | 28.1% | 30.4% | 43.8% |
| Operating Expenses | |||
| Research & Development | $1.6M | $491.4K | — |
| SG&A Expense | $3.7M | $1.1M | $153.1K |
| Operating Income | $-5.3M | $-1.5M | $-9.8K |
| Operating Margin | -883.3% | -286.5% | -2.8% |
| Interest Expense | — | — | — |
| Pretax Income | $-8.3M | $-1.4M | $17.7K |
| Income Tax Expense | $-1.5K | $25.1K | $4.1K |
| Net Income | $-8.3M | $-1.4M | $13.6K |
| Net Margin | -1,392.6% | -276.6% | 3.9% |
| EPS (Basic) | $-0.12 | $-0.02 | $0.00 |
| EPS (Diluted) | $-0.12 | $-0.02 | $0.00 |
| Shares Outstanding (Basic) | 66.7M | 64.7M | 64.7M |
| Shares Outstanding (Diluted) | 66.7M | 64.7M | 64.7M |
| Dividends Per Share | — | — | — |